We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

261 hedge funds and large institutions have $1.46B invested in Pacira BioSciences in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 96 increasing their positions, 86 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

12% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 86

1% more funds holding

Funds holding: 258 → 261 (+3)

8% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 38

4% more call options, than puts

Call options by funds: $6.41M | Put options by funds: $6.14M

0.09% less ownership

Funds ownership: 102.18% → 102.08% (-0.09%)

23% less capital invested

Capital invested by funds: $1.88B → $1.46B (-$427M)

Holders
261
Holders Change
+3
Holders Change %
+1.16%
% of All Funds
4.14%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
41
Increased
96
Reduced
86
Closed
38
Calls
$6.41M
Puts
$6.14M
Net Calls
+$275K
Net Calls Change
-$1M

Top Buyers

Rank Fund Capital Flow
1
Macquarie Group
Macquarie Group
Australia
+$33.7M
2
RCMNY
Rubric Capital Management (New York)
New York
+$16.6M
3
PM
Prosight Management
Texas
+$12M
4
AAP
Ardsley Advisory Partners
Connecticut
+$11.2M
5
CC
Clearline Capital
New York
+$10.8M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$26.2M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$25.8M
3
Invesco
Invesco
Georgia
-$16.9M
4
Jennison Associates
Jennison Associates
New York
-$12.4M
5
PCM
Portolan Capital Management
Massachusetts
-$8.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
276
Boothbay Fund Management
New York
– -$433K -10,816 Closed
KeyBank National Association
277
KeyBank National Association
Ohio
– -$388K -9,683 Closed
PCIA
278
Prime Capital Investment Advisors
Kansas
– -$329K -8,221 Closed
SGI
279
Summit Global Investments
Utah
– -$322K -8,044 Closed
VRS
280
Virginia Retirement Systems
Virginia
– -$297K -7,400 Closed
PCM
281
Prelude Capital Management
New York
– -$280K -6,990 Closed
MAM
282
Martingale Asset Management
Massachusetts
– -$261K -6,507 Closed
AAM
283
Azzad Asset Management
Virginia
– -$249K -6,204 Closed
MC
284
Maverick Capital
Texas
– -$233K -5,823 Closed
RJFSA
285
Raymond James Financial Services Advisors
Florida
– -$229K -5,713 Closed
BFG
286
Bouchey Financial Group
New York
– -$220K -5,500 Closed
SW
287
SVB Wealth
Massachusetts
– -$217K -5,424 Closed
IGWM
288
ICA Group Wealth Management
Colorado
– -$36.1K -900 Closed
PI
289
PineBridge Investments
New York
– -$16.3K -408 Closed
EC
290
Elequin Capital
New York
– -$2.77K -69 Closed
PFBT
291
Parkside Financial Bank & Trust
Missouri
– -$1.84K -46 Closed
HI
292
Harbour Investments
Wisconsin
– -$521 -13 Closed
WP
293
WealthPLAN Partners
Nebraska
– -$321 -8 Closed
DI
294
Disciplined Investments
Oklahoma
– -$160 -4 Closed
C
295
Covestor
United Kingdom
– -$36 -1 -25%
CAL
296
Capital Advisors Ltd
Ohio
– +$288 +8 New
SFG
297
Steward Financial Group
Texas
– +$288 +8 New
8 9 10 11
12

PCRX Hedge Fund Activity: Q3 2023 in Review

261 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2023, worth a combined $1.46B — down 23% from $1.88B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PCRX positions and 38 closed out — a net gain of 3 holders — while 96 added to existing stakes and 86 trimmed.

The largest buyer was Macquarie Group, adding an estimated $33.7M. The largest seller was Citadel Advisors, cutting an estimated $26.2M.

  • 261 institutional investors held Pacira BioSciences (PCRX) as of Q3 2023, up from 258 in Q2 2023.
  • Funds reported $1.46B of Pacira BioSciences stock for Q3 2023, down 23% quarter-over-quarter.
  • 41 funds opened new Pacira BioSciences positions in Q3 2023 and 38 closed out, a net change of +3 holders.
  • The largest Pacira BioSciences buyer in Q3 2023 was Macquarie Group, an estimated $33.7M added.
  • The largest Pacira BioSciences seller in Q3 2023 was Citadel Advisors, an estimated $26.2M sold.

Based on aggregated 13F filings for Q3 2023.